Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.